The global digital dose inhaler market size was estimated to be USD 13.85 billion in 2023 and is expected to reach at USD 104.3 billion by 2033 with a CAGR of 20.15% during the forecast period 2023-2033. Rising demand for digital dose inhalers, growing prevalence of chronic respiratory diseases such as asthma, respiratory disorders, & Chronic Obstructive Pulmonary Disease (COPD), surge in need to effectively monitor the date and time of dosing, increasing geriatric population suffering from respiratory disorders, rising demand for technologically advanced respiratory devices, and surge in innovative product launches are some of the key factors boosting the market growth.
Surge in innovative product launches is predicted to boost the market growth during the forecast period. For instance, in June 2021, Glenmark Pharmaceuticals Ltd has launched Tiogiva in the UK, which is a bioequivalent alternative to Tiotropium Bromide dry powder inhaler (DPI). It is intended for the treatment and control of chronic obstructive pulmonary disease (COPD).
By Product, Dry powder inhalers was the highest revenue-grossing segment in the global digital dose inhaler market in 2022 owing to growing prevalence of chronic respiratory diseases such as Asthma & COPD, rising demand for technologically advanced respiratory devices, increasing research & development activities, and surge in launch of advanced & effective DPI products. For instance, in December 2020, Berry Global has unveiled the RS01 single-dose dry powder inhaler, equipped with integrated sensors and digital functionalities. The RS01 provides individualized assistance to improve adherence and inhaler technique by tracking inhaler usage and connecting to a companion app. Additionally, Metered dose inhaler is predicted to grow at fastest CAGR during the forecast period owing to the increasing healthcare expenditure, rising prevalence of respiratory diseases, growing technological advancements in the development of inhalation medications, and surge in introduction of advanced products.
By Type, Branded was the highest revenue-grossing segment in the global digital dose inhaler market in 2022 owing to surge in demand for the development of new respiratory medications, increasing use of branded drug inhalation, rising healthcare expenditure, growing investment in R&D activities by key market players, and surge in product approvals. For instance, in September 2020, GlaxoSmithKline plc and Innoviva, Inc. have declared that the US Food and Drug Administration (FDA) has granted approval for a new indication of Trelegy Ellipta. This approval allows the use of Trelegy Ellipta for treating asthma in patients who are 18 years old and above, in addition to its existing authorization for patients with chronic obstructive pulmonary disease (COPD). Additionally, generic is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness regarding the benefits of generic drugs and growing demand for cost-effective medications.
By Application, Chronic obstructive pulmonary disease (COPD) was the highest revenue-grossing segment in the global digital dose inhaler market in 2022 owing to the increasing prevalence of COPD and rising product approvals by regulatory bodies. Additionally, asthma is predicted to grow at a fastest CAGR during the forecast period owing to the surge in number of asthma patients and increasing launch of innovative products. For instance, in September 2022, Teva Pharmaceutical Industries Ltd. has launched two digital inhalers in the United States: ArmonAir Digihaler (containing fluticasone propionate) and AirDuo Digihaler (containing fluticasone propionate and salmeterol).
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of respiratory disorders, growing product launches, surge in awareness regarding the currently available hi-tech respiratory devices, rising launch of advanced products. For instance, In February 2022, HeroTracker Sense is a cutting-edge digital respiratory health product offered by Aptar Pharma. This technology turns a regular metered dose inhaler into an intelligent connected healthcare device. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing geriatric population, rising healthcare expenditures, increasing research & development activities, and surge in partnerships & collaborations within market players for the development & launch of novel products. For instance, in January 2020, In collaboration with Lupin Ltd., Aptar Pharma, a company specializing in drug delivery, has unveiled ADHERO, India's inaugural connectivity-enabled device for metered dose inhalers (MDIs).
Surge in innovative product launches is predicted to boost the market growth during the forecast period. For instance, in June 2021, Glenmark Pharmaceuticals Ltd has launched Tiogiva in the UK, which is a bioequivalent alternative to Tiotropium Bromide dry powder inhaler (DPI). It is intended for the treatment and control of chronic obstructive pulmonary disease (COPD).
By Product, Dry powder inhalers was the highest revenue-grossing segment in the global digital dose inhaler market in 2022 owing to growing prevalence of chronic respiratory diseases such as Asthma & COPD, rising demand for technologically advanced respiratory devices, increasing research & development activities, and surge in launch of advanced & effective DPI products. For instance, in December 2020, Berry Global has unveiled the RS01 single-dose dry powder inhaler, equipped with integrated sensors and digital functionalities. The RS01 provides individualized assistance to improve adherence and inhaler technique by tracking inhaler usage and connecting to a companion app. Additionally, Metered dose inhaler is predicted to grow at fastest CAGR during the forecast period owing to the increasing healthcare expenditure, rising prevalence of respiratory diseases, growing technological advancements in the development of inhalation medications, and surge in introduction of advanced products.
By Type, Branded was the highest revenue-grossing segment in the global digital dose inhaler market in 2022 owing to surge in demand for the development of new respiratory medications, increasing use of branded drug inhalation, rising healthcare expenditure, growing investment in R&D activities by key market players, and surge in product approvals. For instance, in September 2020, GlaxoSmithKline plc and Innoviva, Inc. have declared that the US Food and Drug Administration (FDA) has granted approval for a new indication of Trelegy Ellipta. This approval allows the use of Trelegy Ellipta for treating asthma in patients who are 18 years old and above, in addition to its existing authorization for patients with chronic obstructive pulmonary disease (COPD). Additionally, generic is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness regarding the benefits of generic drugs and growing demand for cost-effective medications.
By Application, Chronic obstructive pulmonary disease (COPD) was the highest revenue-grossing segment in the global digital dose inhaler market in 2022 owing to the increasing prevalence of COPD and rising product approvals by regulatory bodies. Additionally, asthma is predicted to grow at a fastest CAGR during the forecast period owing to the surge in number of asthma patients and increasing launch of innovative products. For instance, in September 2022, Teva Pharmaceutical Industries Ltd. has launched two digital inhalers in the United States: ArmonAir Digihaler (containing fluticasone propionate) and AirDuo Digihaler (containing fluticasone propionate and salmeterol).
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of respiratory disorders, growing product launches, surge in awareness regarding the currently available hi-tech respiratory devices, rising launch of advanced products. For instance, In February 2022, HeroTracker Sense is a cutting-edge digital respiratory health product offered by Aptar Pharma. This technology turns a regular metered dose inhaler into an intelligent connected healthcare device. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing geriatric population, rising healthcare expenditures, increasing research & development activities, and surge in partnerships & collaborations within market players for the development & launch of novel products. For instance, in January 2020, In collaboration with Lupin Ltd., Aptar Pharma, a company specializing in drug delivery, has unveiled ADHERO, India's inaugural connectivity-enabled device for metered dose inhalers (MDIs).
Segmentation: Digital Dose Inhaler Market Report 2022 - 2033
Digital Dose Inhaler Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
- Metered Dose Inhalers
- Dry Powder Inhalers
Digital Dose Inhaler Market Analysis & Forecast by Type 2022 - 2033 (Revenue USD Bn)
- Generic
- Branded
Digital Dose Inhaler Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others
Digital Dose Inhaler Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Digital Dose Inhaler Market: Product Estimates & Trend Analysis
8. Digital Dose Inhaler Market: Type Estimates & Trend Analysis
9. Digital Dose Inhaler Market: Application Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Digital Dose Inhaler Market
12. Europe Global Digital Dose Inhaler Market
13. Asia Pacific Global Digital Dose Inhaler Market
14. Latin America Global Digital Dose Inhaler Market
15. MEA Global Digital Dose Inhaler Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- AstraZeneca Plc
- BEXIMCO Pharmaceuticals
- Glenmark Pharmaceuticals Ltd.
- Sensirion AG
- Propeller Health
- Teva Pharmaceutical Industries Ltd
- 3M Company
- Opko Health Inc.
- GlaxoSmithKline Plc
- Philips Respironics
- Mundipharma Deutschland GmbH & Co. KG
- Novartis International AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 13.85 Billion |
| Forecasted Market Value ( USD | $ 104.3 Billion |
| Compound Annual Growth Rate | 20.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
